Human CXCR4 / CD184 Protein, Fc Tag

AIDD‑Ready
Cat. No. / Size
Price
Availability
Qty
CX4-H5269-50ug
$310.00
In Stock - Delivery in 1-2 business days
CX4-H5269-1mg (500ug X 2)
$2,720.00
In Stock - Delivery in 2 weeks
CX4-H5269
Sub-Total :
$ 0
0
Add to Cart
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
0
Add to Cart
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

CXCR4, CD184, Fusin, D2S201E, FB22, HM89, HSY3RR, LAP3, LCR1, LESTR, NPY3R, NPYR, NPYRL, NPYY3R, WHIM

Source

Human CXCR4, Fc Tag (CX4-H5269) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ser 46 (Accession # AAH20968.1).

Molecular Characterization

This protein carries a human IgG1 Fc tag at the N-terminus.

The protein has a calculated MW of 32.3 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

Background

A chemokine receptor with pleiotropic roles in hematopoietic stem cell homing to bone marrow and cancer metastasis. The CXCL12/CXCR4 axis is a key retention signal for stem cells and malignant plasma cells. Antagonists (plerixafor) are standard-of-care for stem cell mobilization and are being developed for solid tumor therapy.